Elenagen, a novel DNA immunotherapy for the deadliest form of ovarian cancer, delays disease progression - ecancer
ecancer,
CureLab Oncology, a clinical-stage, pre-IPO biotech company, announced that its novel biological agent, Elenagen, has been…
CureLab Oncology, a clinical-stage, pre-IPO biotech company, announced that its novel biological agent, Elenagen, has been…
Oncology/Hematology > Other Cancers News, features, and commentary about cancer-related issues by Charles Bankhead, Senior…
CureLab Oncology, a clinical-stage, pre-IPO biotech company, announced that its novel biological agent, Elenagen, has been…
BOSTON, February 22, 2024: CureLab Oncology, a clinical-stage, pre-IPO biotech company, announced that its novel biological…